Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
BUZZ - Australia's EVT stock rises due to first-quarter EBITDA growth

BUZZ - Australia's EVT stock rises due to first-quarter EBITDA growth

路透社路透社2026/10/23 01:30
Show original

- ** EVT (EVT.AX) shares rose as much as 4% to AUD 15.490, reaching their highest level since August 26

** The stock recorded its largest intraday gain since September 25

** The entertainment company announced (link) first quarter FY2027 EBITDA of AUD 72.5 million, a 17% year-on-year increase on a normalized basis

** EVT maintains an optimistic outlook for FY2027 and expects the hotels business to reach a historic high

** The company expects FY2027 EBITDA for Thredbo Alpine Resort to be between AUD 16 million and AUD 20 million, compared to Visible Alpha's analyst consensus of AUD 16.9 million; the FY2026 figure was AUD 21 million

** Citi rates the stock as "Buy" with a target price of AUD 17.55

** Year-to-date, the share price has risen 19.5%


(To assist non-native English speakers, Reuters has automated the translation of its reports into several other languages. Because automated translation may contain errors or may not include necessary context, Reuters does not guarantee the accuracy of the automated translation and provides it for readers' convenience only. Reuters assumes no responsibility for any damage or loss caused by the use of this automated translation function.)

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

GM cancels long-term rare earth permanent magnet supply agreement in the US; supplier initiates arbitration

General Motors (GM.US) has canceled a long-term supply agreement with a U.S. rare earth permanent magnet manufacturer, and both parties are currently undergoing arbitration.

智通财经•2026/10/23 03:27
GM cancels long-term rare earth permanent magnet supply agreement in the US; supplier initiates arbitration

Allergy and autoimmune biotechnology company Lycia Therapeutics (LYCA.US) will be listed on Nasdaq tonight! IPO priced at $18 per share, aiming to raise $317.5 millions.

Lycia will issue 17.64 million shares at a price of $18 per share to raise $317.5 million.

智通财经•2026/10/23 02:47